VF
PTCT icon

VitalStone Financial’s PTC Therapeutics PTCT Stock Holding History

VitalStone Financial’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$2.56K Sell
69
-9,298
-99% -$311K ﹤0.01% 371
2024
Q2 		$286K Buy
+9,367
New +$303K 0.21% 92

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VitalStone Financial's PTCT Position: Q3 2024 in Review

VitalStone Financial reduced its PTC Therapeutics (PTCT) stake by 99% in Q3 2024, selling an estimated $311K and leaving 69 shares worth $2.56K. The position accounts for ﹤0.01% of the portfolio, ranked #371.

VitalStone Financial first reported a position in PTCT in Q2 2024 and has held it in 2 quarters since. The position peaked at $286K in Q2 2024. 203 funds tracked by Wall St. Rank hold PTCT as of Q3 2024.

  • VitalStone Financial held 69 shares of PTC Therapeutics worth $2.56K as of Q3 2024.
  • VitalStone Financial sold 9,298 PTC Therapeutics shares in Q3 2024, an estimated $311K.
  • PTC Therapeutics made up ﹤0.01% of VitalStone Financial's portfolio in Q3 2024, its #371 holding.
  • VitalStone Financial first reported a position in PTC Therapeutics in Q2 2024 and has held it in 2 quarters since.
  • VitalStone Financial's PTC Therapeutics position peaked at $286K in Q2 2024.
  • 203 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2024.

Based on VitalStone Financial's 13F filing for Q3 2024, filed 11 Oct 2024.